Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.32, $0.10 better than the analyst estimate of $0.22. Revenue for the quarter came in at $88.6 million versus the consensus estimate of $90.14 million.

GUIDANCE:

Corcept Therapeutics reaffirms FY2020 revenue of $355-375 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.